{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-25-000041","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.660093+00:00","generated_at":"2026-05-17T19:38:10.839802+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials","bullets":["Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.","Cash, cash equivalents and marketable securities $354M as of June 30, 2025; expected runway into Q2 2027.","First patient dosed in ELEVATE-44-201 for DMD exon 44; data from first cohort expected H1 2026.","Initiated ELEVATE-45-201 for exon 45; first patient dosing on track Q3 2025; cohort 1 data mid-2026.","Expanded leadership: Navid Khan as SVP Medical Affairs, Kiran Patki as SVP Clinical Development; Maha Radhakrishnan joined Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-25-000041","json":"https://secwatch.observer/filing/0001689375-25-000041.json","markdown":"https://secwatch.observer/filing/0001689375-25-000041.md","text":"https://secwatch.observer/filing/0001689375-25-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/0001689375-25-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/trda-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:38:10.839802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}